Pharma's Market
- Monday, 9 Nov 2009 2:26 PM ETBy: Mike Huckman
Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies. » Read more - Friday, 6 Nov 2009 11:01 AM ETBy: Mike Huckman
Stacy and Clinton definitely had nothing to do with it, but Sanofi-Pasteur (the vaccines division of Sanofi-Aventis) greets visitors with a "What Not To Wear" brochure. » Read more - Wednesday, 4 Nov 2009 11:14 AM ETBy: Mike Huckman
I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck. » Read more - Tuesday, 3 Nov 2009 1:46 PM ETBy: Mike Huckman
Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman. » Read more - Monday, 2 Nov 2009 12:32 PM ETBy: Mike HuckmanOver the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news. » Read more
- Friday, 30 Oct 2009 12:46 PM ETBy: Mike Huckman
I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill. » Read more - Thursday, 29 Oct 2009 2:59 PM ETBy: Mike HuckmanOn a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck and the company it's buying, Schering-Plough, are sliding. So, what gives? » Read more
- Wednesday, 28 Oct 2009 11:15 AM ETBy: Mike Huckman
GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter. » Read more
ABOUT PHARMA'S MARKET
Pharma's Market is more than just a play on words. Think of this blog written by Mike Huckman as a “farmer's market”—a place where you'll find a wide assortment of fresh stuff related to the drug, biotech and medical device industries. Mike will try to harvest topics from fertile, untilled ground. And yes, occasionally, he'll go off the farm.
BIO
Mike Huckman is the author of CNBC.com’s Pharma’s Market and CNBC's Pharmaceuticals Reporter covering the drug, biotechnology and medical device industries. Huckman joined the network in 2000 and is based at the network’s global headquarters in Englewood Cliffs, N.J. Read full bio here.
MIKE HUCKMAN'S FAVORITE LINKS
SPECIAL REPORT
MOST SHARED
- Health-Care Reform Does Little To Contain Costs: Analysts
- Home Prices Sank Further In Most Parts of US in 3rd Quarter
- 'Peak Oil' Closer Than IEA Forecasts Show: Report
- News Corp. May Pull Content From Google Searches
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Treasurys Head Lower as Auction Fails to Impress
- America Is On Sale
- Trader Tax Sound Off
- HALFTIME REPORT: How to Trade Senator Dodd's Financial Reforms
- The Lloyd's Prayer
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Passive Job Search Strategies
- Back Off, Regulators!
- America Is On Sale
- Warren Buffett and the Crisis: 'Brilliant Moves Interspersed with Some Surprising Errors'
- Chrysler Makes Smart Call Staying Unplugged—For Now
- Yankees Team Signed Ball Selling For $3,500
- Is 10% Unemployment Good for Stocks?
RSS FEED
» Help
powered by digg
About CNBC | Site Map | Privacy Policy | Terms of Service | Video Reprints | Advertise | Help | Contact
Partners: AOL Money | BloggingStocks.com
Partners: AOL Money | BloggingStocks.com
Data is a real-time snapshot *Data is delayed at least 15 minutesGlobal Business and Financial News, Stock Quotes, and Market Data and Analysis
© 2009 CNBC, Inc. All Rights Reserved.
A Division of NBC Universal
